Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
نویسندگان
چکیده
منابع مشابه
Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
Immunotherapy has recently become widely used in lung cancer. Many oncologists are focused on cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death ligand-1 (PD-L1) and programmed cell death-1 (PD-1). Immunotherapy targeting the PD-1/PD-L1 checkpoints has shown promising efficacy in non-small cell lung cancer (NSCLC), but questions remain to be answered. Among them is whether the sim...
متن کاملImmune checkpoint blockade in ovarian cancer
Increased numbers of tumour infiltrating T‑cells have long been associated with a better prognosis in ovarian cancer, which has led to the general assumption of a relevant impact of T‑cellular anti-tumour immunity in this disease. As a consequence of this knowledge, a multitude of immunologic therapies has emerged over the past years. Although some reports could evidence a successful induction ...
متن کاملImmune Checkpoint Blockade in Cancer Therapy.
Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and additional regulatory appr...
متن کاملImmune checkpoint inhibitors in cancer therapy.
In recent years immune checkpoint inhibitors have garnered attention as being one of the most promising types of immunotherapy on the horizon. There has been particular focus on the immune checkpoint molecules, cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) which have been shown to have potent immunomodulatory effects through their function as negative regu...
متن کاملImmune Checkpoint Inhibition in Advanced Cancer
Following the success of single agent CTLA-4 and PD-1 inhibition, focus has shifted to the study of novel combinations of immune therapeutics with the goal of improving efficacy. A major breakthrough was seen in CheckMate 067 as dual PD1/CTLA4 blockade demonstrated robust and often durable responses. However, this efficacy came at the cost of considerable toxicity, as ≥ 50% of patients on combi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Science
سال: 2016
ISSN: 1347-9032,1349-7006
DOI: 10.1111/cas.12986